Assenagon Asset Management S.A. Raises Stock Holdings in Merck & Co., Inc. $MRK

Key Points

• Assenagon Asset Management sharply increased its Merck stake by 263.7% in the second quarter, purchasing 1.96 million additional shares. The fund now owns nearly 2.7 million shares valued at approximately $347.3 million.
• Merck exceeded quarterly earnings and revenue expectations, reporting revenue of $16.61 billion and raising confidence in its 2026 outlook. The company also declared a quarterly dividend of $0.85 per share, yielding about 2.7% annually.
• Wall Street sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $134.56. However, investors continue to weigh Keytruda’s approaching 2028 patent cliff and mixed pipeline developments.

Assenagon Asset Management S.A. raised its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 263.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,702,992 shares of the company's stock after purchasing an additional 1,959,778 shares during the quarter. Assenagon Asset Management S.A. owned 0.11% of Merck & Co., Inc. worth $347,334,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in MRK. Kingdom Financial Group LLC. purchased a new position in shares of Merck & Co., Inc. in the 4th quarter worth approximately $25,000. Prosperity Bancshares Inc purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at $26,000. Abound Financial LLC purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at $26,000. IFC & Insurance Marketing Inc. bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth about $31,000. Finally, High Note Wealth LLC lifted its holdings in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company's stock worth $31,000 after acquiring an additional 109 shares during the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Stock Down 0.0%

NYSE:MRK opened at $128.27 on Friday. The company has a market cap of $316.81 billion, a price-to-earnings ratio of 102.62, a price-to-earnings-growth ratio of 5.14 and a beta of 0.19. Merck & Co., Inc. has a twelve month low of $77.58 and a twelve month high of $135.05. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The stock has a fifty day simple moving average of $123.78 and a 200-day simple moving average of $119.04.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to analysts' expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The business's revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the prior year, the business posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts anticipate that Merck & Co., Inc. will post 2.72 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be paid a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.7%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.'s payout ratio is 272.00%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on MRK. Citigroup assumed coverage on shares of Merck & Co., Inc. in a report on Wednesday, May 6th. They set a "neutral" rating and a $125.00 price target on the stock. BMO Capital Markets raised their price objective on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an "outperform" rating in a research note on Monday, July 13th. Bank of America boosted their target price on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a "buy" rating in a research report on Tuesday, June 30th. Guggenheim upped their target price on Merck & Co., Inc. from $145.00 to $146.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. Thirteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company's stock. According to data from MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of "Moderate Buy" and an average target price of $134.56.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst price-target increase: Guggenheim raised its Merck price target from $145 to $146 and maintained a Buy rating, implying meaningful upside from the referenced share price. This reinforces positive Wall Street sentiment. Benzinga
• Positive Sentiment: Keytruda gains another approval: Health Canada approved Keytruda with enfortumab vedotin for certain cisplatin-ineligible patients with muscle-invasive bladder cancer, expanding the drug’s use and potentially supporting sales before its major patent expirations. Health Canada approves Keytruda treatment
• Positive Sentiment: Pipeline and post-Keytruda strategy: Merck’s second-quarter commentary highlighted new product launches, pipeline progress and efforts to diversify into areas including vaccines, infectious diseases, hematology, cardiopulmonary disease and obesity. The company also raised its 2026 sales outlook, improving confidence in near-term execution. MRK Q2 earnings call
• Neutral Sentiment: Dividend comparison: Merck’s latest results have renewed debate over whether it offers a better income opportunity than Pfizer. The discussion may attract dividend-focused investors, but it does not represent a new company-specific catalyst. Pfizer or Merck dividend comparison
• Negative Sentiment: Keytruda patent risk remains central: Keytruda is approaching a significant patent cliff beginning in 2028. Merck is accelerating acquisitions and partnerships to offset the eventual revenue decline, but those investments can pressure earnings and increase execution risk. Merck is racing beyond Keytruda
• Negative Sentiment: Mixed pipeline development: Merck discontinued tulisokibart development in systemic sclerosis-associated interstitial lung disease, although the drug continues to be evaluated in other indications. The setback highlights clinical-development risk as Merck builds its post-Keytruda portfolio. MSD anti-TL1A trial update

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source